Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL
Status:
Completed
Trial end date:
2019-02-07
Target enrollment:
Participant gender:
Summary
Primary objective: The primary objective of this study is to evaluate the pharmacokinetics
(PK) of EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal
surgery.
Secondary objective: The secondary objective of this study is to evaluate the safety of
EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal surgery.